The funding will help accelerate the commercialization of the company's dipstick-based assay, which is designed to identify many SARS-CoV-2 genetic variants at once.
The funding will help accelerate the commercialization of the company's dipstick-based assay, which is designed to identify many SARS-CoV-2 genetic variants at once.